share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K:重大事件
美股sec公告 ·  05/17 16:50
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VVOS, has reported a compliance issue in a Current Report on Form 8-K filed with the SEC. The report, dated May 17, 2024, with events reported as of May 16, 2024, details the company's ongoing struggle to meet the Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Despite previous capital raising efforts that led the company to believe it had regained compliance as of March 19, 2024, a new notice from Nasdaq on May 16, 2024, indicated that Vivos Therapeutics' stockholders' equity had fallen below the required threshold. As a result, Nasdaq has initiated delisting proceedings. The company has appealed this determination and is actively working...Show More
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Capital Market under the trading symbol VVOS, has reported a compliance issue in a Current Report on Form 8-K filed with the SEC. The report, dated May 17, 2024, with events reported as of May 16, 2024, details the company's ongoing struggle to meet the Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. Despite previous capital raising efforts that led the company to believe it had regained compliance as of March 19, 2024, a new notice from Nasdaq on May 16, 2024, indicated that Vivos Therapeutics' stockholders' equity had fallen below the required threshold. As a result, Nasdaq has initiated delisting proceedings. The company has appealed this determination and is actively working to regain compliance. The appeal has stayed the delisting process, allowing Vivos Therapeutics' common stock to remain listed on Nasdaq pending the outcome of the hearing. The company acknowledges the risk of being unable to demonstrate compliance and the potential material adverse effects of delisting, including impacts on stock price, trading, capital raising, and reputation.
Vivos Therapeutics, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司,交易代碼爲VVOS,該公司在向美國證券交易委員會提交的8-K表最新報告中報告了合規問題。該報告日期爲2024年5月17日,報告了截至2024年5月16日的事件,詳細介紹了該公司爲滿足納斯達克上市規則5550(b)(1)而持續進行的努力,該規則要求最低股東權益爲250萬美元。儘管此前的籌資努力使該公司相信截至2024年3月19日已恢復合規,但納斯達克於2024年5月16日發佈的新通知顯示,Vivos Therapeutics的股東權益已降至規定的門檻以下。因此,納斯達克啓動了退市程序。該公司已對該裁決提出上訴,並正在積極努力恢復合規。上訴暫停了退市程序,允許Vivos Therapeutics的普通股在聽證會得出結果之前繼續在納斯達克上市。該公司承認無法證明合規的風險以及退市的潛在重大不利影響,包括對股價、交易、籌資和聲譽的影響。
Vivos Therapeutics, Inc. 是一家在納斯達克資本市場上市的特拉華州註冊公司,交易代碼爲VVOS,該公司在向美國證券交易委員會提交的8-K表最新報告中報告了合規問題。該報告日期爲2024年5月17日,報告了截至2024年5月16日的事件,詳細介紹了該公司爲滿足納斯達克上市規則5550(b)(1)而持續進行的努力,該規則要求最低股東權益爲250萬美元。儘管此前的籌資努力使該公司相信截至2024年3月19日已恢復合規,但納斯達克於2024年5月16日發佈的新通知顯示,Vivos Therapeutics的股東權益已降至規定的門檻以下。因此,納斯達克啓動了退市程序。該公司已對該裁決提出上訴,並正在積極努力恢復合規。上訴暫停了退市程序,允許Vivos Therapeutics的普通股在聽證會得出結果之前繼續在納斯達克上市。該公司承認無法證明合規的風險以及退市的潛在重大不利影響,包括對股價、交易、籌資和聲譽的影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息